BioAtla, Inc. (NASDAQ:BCAB) Receives Average Recommendation of “Hold” from Analysts

BioAtla, Inc. (NASDAQ:BCAB) has been assigned a consensus rating of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $4.00.

A number of research firms recently commented on BCAB. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAtla in a report on Friday, January 9th. Rodman & Renshaw initiated coverage on BioAtla in a research note on Tuesday, January 13th. They issued a “buy” rating and a $4.00 price target on the stock.

Institutional Investors Weigh In On BioAtla

A number of institutional investors have recently made changes to their positions in BCAB. Woodline Partners LP purchased a new stake in shares of BioAtla in the 1st quarter valued at approximately $26,000. Sheets Smith Investment Management acquired a new stake in BioAtla in the 3rd quarter valued at approximately $46,000. Susquehanna International Group LLP raised its position in BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after purchasing an additional 177,760 shares during the period. Millennium Management LLC purchased a new stake in BioAtla in the third quarter valued at approximately $235,000. Finally, Acadian Asset Management LLC lifted its stake in BioAtla by 968.9% during the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after purchasing an additional 1,531,994 shares in the last quarter. 77.23% of the stock is currently owned by institutional investors and hedge funds.

BioAtla Trading Up 10.8%

BioAtla stock opened at $0.21 on Friday. The company has a 50-day moving average price of $0.53 and a 200 day moving average price of $0.59. BioAtla has a 12-month low of $0.14 and a 12-month high of $1.43. The stock has a market cap of $13.36 million, a P/E ratio of -0.18 and a beta of 1.10.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.04. As a group, analysts forecast that BioAtla will post -1.46 EPS for the current year.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.